NCT07009847

An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

A Case Control Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,308 (estimated)
• Sponsor: Serum Institute of India Pvt. Ltd. · Industry
• Sex: All
• Age: 5 Months
• Healthy volunteers: Accepted

Summary

This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are at an increased risk of deaths (all-cause). Clinical malaria, severe malaria and death (all-cause) cases will be enrolled in study. For each case (severe or death) 4 controls matched for age and neighborhood will be enrolled whereas for clinical malaria case, 1 matched control will be enrolled. 1. Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum. 2. Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases in high-transmission perennial areas caused by P. falciparum. 3. Proportion of vaccinated and unvaccinated children in cases of death (all cause) 4. Exploratory effectiveness endpoint: Proportion of vaccinated and unvaccinated children in the hospitalized clinical and severe malaria cases.

Detailed description

The study will be conducted at multiple centers with the appropriate research infrastructure to carry out safety and/or effectiveness research across different countries where the R21/Matrix-M vaccine is (or will be) approved and deployed for vaccination with subsequent population uptake. The cases will be enrolled from hospitals/clinics and the matched controls will be recruited from the community by visiting the neighborhood. Children eligible for receiving R21/Matrix-M vaccine, residing in the geographical area where the vaccine has been deployed will be considered as either cases or controls if they meet the eligibility criteria. All participants will be screened for eligibility after obtaining informed written consent from parents/legal guardians/ caregivers. Surveillance and detection of cases: Cases qualifying the case definitions of clinical or severe malaria, cases will be recruited from the hospitals, clinics or the sub-sites. For deaths, cases will be recruited from the hospital or the community. Cause of death will be ascertained from hospital or available medical records as well as discussions with family or healthcare professionals who may have been involved. Identification of controls: Four controls for each case will be recruited by study physician or field staff from community for severe malaria and death cases. For clinical malaria cases in high-transmission perennial areas, case: control ratio will be 1:1. Controls will be matched for age and neighborhood. Controls should be residing in the same neighborhood as the respective case, but not from the same house. Living controls will be enrolled against the death cases. Vaccination status will be confirmed from the vaccination/immunization cards, hospital/clinic records, home based registers, or national immunization database. History from the parents/ guardians/ caregivers will be considered in case of non-vaccination. Field staff may visit the homes of controls and (if required) cases for collection of the required data.

Conditions

• Malaria,Falciparum
• Morality

Interventions

Type	Name	Description
OTHER	Case control study of clinical malaria	Case control study of clinical malaria
OTHER	Case control study of severe malaria	Case control study of severe malaria
OTHER	Case control study of death (all cause)	Case control study of death (all cause)

Timeline

• Start date: 2025-06-16
• Primary completion: 2026-10-30
• Completion: 2026-12-31
• First posted: 2025-06-08
• Last updated: 2025-08-13

Locations

5 sites across 4 countries: Burkina Faso, Côte d’Ivoire, Nigeria, Uganda